Your browser doesn't support javascript.
loading
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria.
Trama, Ashley M; Moody, M Anthony; Alam, S Munir; Jaeger, Frederick H; Lockwood, Bradley; Parks, Robert; Lloyd, Krissey E; Stolarchuk, Christina; Scearce, Richard; Foulger, Andrew; Marshall, Dawn J; Whitesides, John F; Jeffries, Thomas L; Wiehe, Kevin; Morris, Lynn; Lambson, Bronwen; Soderberg, Kelly; Hwang, Kwan-Ki; Tomaras, Georgia D; Vandergrift, Nathan; Jackson, Katherine J L; Roskin, Krishna M; Boyd, Scott D; Kepler, Thomas B; Liao, Hua-Xin; Haynes, Barton F.
Afiliação
  • Trama AM; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA. Electronic address: ashley.trama@dm.duke.edu.
  • Moody MA; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Pediatrics, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Alam SM; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Jaeger FH; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Lockwood B; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Parks R; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Lloyd KE; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Stolarchuk C; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Scearce R; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Foulger A; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Marshall DJ; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Whitesides JF; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Jeffries TL; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Wiehe K; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Morris L; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
  • Lambson B; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
  • Soderberg K; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Hwang KK; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Tomaras GD; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Molecular Genetics and Microbiology, Duke Univers
  • Vandergrift N; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Jackson KJL; Department of Pathology, Stanford University, Palo Alto, CA 94305, USA.
  • Roskin KM; Department of Pathology, Stanford University, Palo Alto, CA 94305, USA.
  • Boyd SD; Department of Pathology, Stanford University, Palo Alto, CA 94305, USA.
  • Kepler TB; Department of Microbiology, Boston University, Boston, MA 02215, USA.
  • Liao HX; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA.
  • Haynes BF; Duke Human Vaccine Institute, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine and Duke Global Health Institute, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine a
Cell Host Microbe ; 16(2): 215-226, 2014 Aug 13.
Article em En | MEDLINE | ID: mdl-25121750
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Proteína gp41 do Envelope de HIV / Infecções por HIV / HIV-1 / Microbiota / Íleo Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / Proteína gp41 do Envelope de HIV / Infecções por HIV / HIV-1 / Microbiota / Íleo Idioma: En Ano de publicação: 2014 Tipo de documento: Article